March 30, 2026
Patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer in Europe may soon have a new bladder-sparing treatment option after the European Medicines Agency’s Committee for […]
March 30, 2026
Katie Palay, who is in her 30s, has been in remission from Hodgkin lymphoma since 2010, but her cancer journey is far from over. A self-described […]
March 30, 2026
Subcutaneous administration of the anti-PD-1 monoclonal antibody toripalimab achieves similar drug exposure as the intravenous formulation in advanced non-squamous non-small cell lung cancer (NSCLC), with similar […]
March 30, 2026
MRI can identify patients with HER2-positive breast cancer who don’t need a full course of neoadjuvant chemotherapy, letting them avoid the toxicity of unnecessary treatment while […]
March 27, 2026
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two drugs for the treatment of adults with small […]
March 27, 2026
The FDA has granted accelerated approval to the gene therapy marnetegragene autotemcel (Kresladi, Rocket Pharmaceuticals) for the treatment of pediatric patients with severe leukocyte adhesion deficiency […]
March 27, 2026
New findings have provided more evidence that omitting carboplatin from standard neoadjuvant therapy in HER2-positive early breast cancer can improve tolerability without compromising short-term efficacy, supporting […]
March 27, 2026
BARCELONA — Elinzanetant reduced the severity and frequency of hot flushes and night sweats in women taking endocrine therapy for breast cancer, it was reported here […]
March 27, 2026
Progression-free survival (PFS) doubled in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations and received osimertinib plus chemotherapy vs those […]